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Abstract
Background: Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can
be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore
the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after
bevacizumab monotherapy for advanced HER2-negative breast cancer.
Methods: Patients had advanced HER2-negative disease that progressed while receiving single-agent bevacizumab
maintenance as a part of a previous chemotherapy plus bevacizumab regimen. Treatment consisted of bi-weekly
durvalumab plus bevacizumab (10 mg/kg each i.v.). Peripheral-blood mononuclear cells (PBMCs) were obtained
before the first durvalumab dose and every 4 weeks and immunophenotyped by flow-cytometry. A fresh pre-
durvalumab tumor biopsy was obtained; gene-expression studies and immunohistochemical staining to assess
vascular normalization and characterize the immune infiltrate were conducted. Patients were classified as “non-
progressors” if they had clinical benefit (SD/PR/CR) at 4 months. The co-primary endpoints were the changes in the
percentage T cell subpopulations in PBMCs in progressors versus non-progressors, and PFS/OS time.
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Results: Twenty-six patients were accrued. Median PFS and OS were 3.5 and 11 months; a trend for a longer OS
was detected for the hormone-positive subset (19.8 versus 7.4 months in triple-negatives; P = 0.11). Clinical benefit
rate at 2 and 4 months was 60% and 44%, respectively, without significant differences between hormone-positive
and triple-negative (P = 0.73). Non-progressors’ tumors displayed vascular normalization features as a result of
previous bevacizumab, compared with generally abnormal patterns observed in progressors. Non-progressors also
showed increased T-effector and T-memory signatures and decreased TREG signatures in gene expression studies in
baseline—post-bevacizumab—tumors compared with progressors. Notably, analysis of PBMC populations before
durvalumab treatment was concordant with the findings in tumor samples and showed a decreased percentage of
circulating TREGs in non-progressors.
Conclusions: This study reporting on sequential bevacizumab+durvalumab in breast cancer showed encouraging
activity in a heavily pre-treated cohort. The correlative studies agree with the preclinical rationale supporting an
immunopriming effect exerted by antiangiogenic treatment, probably by reducing TREGs cells both systemically and
in tumor tissue. The magnitude of this benefit should be addressed in a randomized setting.
Trial registration: (www.clinicaltrials.gov): NCT02802098. Registered on June 16, 2020.
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Background
Single-agent immune checkpoint inhibitors have shown
moderate efficacy in advanced breast cancer [1–5]. Con-
siderable efforts are directed towards enhancing their ac-
tivity, most often in combination with chemotherapy,
but also in chemotherapy-free regimens [6].
Several factors modulate the response of cancer cells
to anti-PD-1/PD-L1 agents, including tumor mutational
burden (TMB), PD-L1 expression, and immune infiltra-
tion [7, 8]. PD-L1 expression rates [9, 10] are usually
low in breast cancer. Several strategies have been sug-
gested to enhance the efficacy of immunotherapy, in-
cluding the manipulation of tumor microenvironment to
enhance T effector cell infiltration and access to the
tumor [11]. Recently, it has been suggested that combin-
ing antiangiogenic therapies and immunotherapies might
increase the effectiveness of immunotherapy [12].
VEGF-A (Vascular Endothelial Growth Factor-A), the
main soluble factor responsible for tumor angiogenesis, is
also involved in creating an immunosuppressive tumor
microenvironment: it prevents dendritic cell (DC) precur-
sors from evolving into mature antigen-presenting DCs
and promotes the development of tumor-associated mac-
rophages [13, 14]. It also fosters the proliferation of im-
munosuppressive cells, limits T cell recruitment into
tumors, and promotes T cell exhaustion [15]. Tumor ves-
sel and stromal abnormality correction (which can be
achieved by antiangiogenics) can restore the immune
function [16]. Preclinical evidence in breast, pancreatic,
and brain tumors and melanoma [17, 18] and clinical re-
sults in renal cell cancer [19] have shown that antiangio-
genic treatment was followed by more efficient T cell
extravasation and tumor infiltration, turning immuno-
logically ‘cold’ into ‘hot’ tumors [17, 18]. Thus, combining
antiangiogenics with immune checkpoint inhibitors
represents a potentially interesting chemo-free regimen.
Several recent trials combining small-molecule antiangio-
genics plus immune checkpoint inhibitors have shown en-
hanced activity particularly in settings where high VEGF
levels are known to drive tumor growth [20]. The role of
VEGF as a driver of breast cancer progression, however,
has been extensively questioned in light of the long-term
results of phase III trials with antiangiogenics [21–24].
The efforts invested in studying immune-boosting com-
binations, however, have paid little attention to the timing
of administration of the “immune enhancer”. The natural
rhythms of innate and adaptive response could be used to
enhance the efficacy of anti-PD-1/PD-L1 agents by com-
bining them with agents in the right sequence [25, 26]. In
that sense, it is possible that pre-treatment with a VEGF-
A inhibitor could exert an immuno-priming effect that
would increase the chance of response to subsequent im-
mune checkpoint blockade and be more effective than
concurrent therapy [26], while causing less adverse events
[12]. We sought to explore a sequential chemotherapy-
free regimen combining the anti-PD-L1 agent durvalumab
with the antiangiogenic agent bevacizumab. In order to
take advantage of the potential “sequential-effects”, pa-
tients had to have experienced disease progression while
on bevacizumab monotherapy prior to entering the trial
(as maintenance treatment after a chemotherapy plus bev-
acizumab regimen). In addition, we sought to find traits in
peripheral-blood mononuclear cells (PBMCs) and tumor
biopsies that informed about the immune priming, in an
attempt to search for novel biomarkers and obtain a better
understanding of the biology of this clinical scenario.
Methods
We performed a prospective, open-label, multicentric,
single-arm, phase IB investigator-initiated study. The
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study was conducted in accordance with the Declaration
of Helsinki and Good Clinical Practice standards and
registered at Clinicaltrials.gov (NCT02802098). Ethics
approval was obtained from the Madrid Regional Gov-
ernment Ethics Board for Drug Research and the
Spanish Agency for Medicine and Health Products
(AEMPS).
Study population
Women ≥ 18 years old were eligible if they had a non-
curable, locally advanced or metastatic HER2-negative
histologically confirmed breast cancer. Given the aca-
demic nature of this study, and the limited funding as a
result of being an independent study, in the context of
current FDA status for bevacizumab, the only option to
execute a pilot trial in order to detect a signal of “prim-
ing effect” was to nest a state-of-the-art set of correlative
studies in patients that were still receiving bevacizumab
as a part of previously FDA-approved bevacizumab+
chemotherapy combination regimens followed by beva-
cizumab maintenance. A clinical trial where candidates
were started on bevacizumab monotherapy was deemed
unrealistic and possibly unethical by the investigators,
and thus, the key inclusion criterion was that it was
mandatory to have been receiving bevacizumab mono-
therapy maintenance for a minimum of 6 weeks as a
part of any bevacizumab-containing regimen prior to
registration, but there was no limit to the number of
previous treatment lines. The only restriction was that
no previous bevacizumab-containing regimens were
allowed (i.e., it had to be the first bevacizumab-
containing regimen that the patients were exposed to).
Other inclusion criteria included negative pregnancy
test, ECOG (Eastern Cooperative Oncology Group) 0–1,
adequate organic function (according to standard defini-
tions), lack of uncontrolled brain metastases, LVEF (Left
Ventricular Ejection Fraction) > 45%, and life expectancy
> 24 weeks. Patients suffering from concurrent severe
conditions, taking anticoagulants, receiving immunosup-
pressants, or with a history of clinically significant bleed-
ing or thromboembolic events within 6 months or study
entry were excluded. Previous treatment with immuno-
therapy was not allowed. Non-measurable disease (e.g.,
bone disease only) was allowed.
Trial design and correlative studies
The treatment consisted of 10 mg/kg i.v. of durvalumab
plus 10 mg/kg i.v. of bevacizumab every 2 weeks. One
cycle was defined as 28 days. Hormone-positive patients
were not allowed to receive hormonal therapy while on
trial. CT (computed tomography) scans were performed
every 8 weeks and disease burden was evaluated accord-
ing to RECIST 1.1 criteria (Response Evaluation Criteria
in Solid Tumors). Toxicity was graded according to NCI
CTC AE V.4.03 (Common Terminology Criteria for Ad-
verse Events). Figure 1 depicts basic trial design.
A peripheral blood sample was obtained on the day of
the first durvalumab dose in order to analyze peripheral-
blood mononuclear cells (PBMCs) subpopulations by
flow cytometry (FACS). Blood sampling for FACS ana-
lysis was repeated on weeks 4, 8, 12, 16, 20, and 24 and
at the end-of-treatment visit. Patients underwent a
tumor biopsy between 5 and 7 days prior to the first
study treatment.
PBMCs immunophenotyping was performed as fol-
lows: blood (~ 30ml) was collected in CPT Cell Prepar-
ation Tubes (BD) and PBMC isolated by centrifugation.
Immunophenotyping was performed by staining 2 × 106
PBMCs with a combination of antibodies (Table S1)
proposed by the Human Immunology Project Consor-
tium to characterize T cell subtypes, regulatory T cells
(TREG), dendritic cells (DC), monocytes, and natural
killer (NK) cells [27]. Stained samples were acquired in a
Gallios cytometer (Beckman Coulter); the gating strategy
for each panel was performed with the Kaluza software
and is shown in Supplementary Figure S1, S2, S3. The
ratio between effector and non-effector T cell subtypes
was calculated by considering the non-effector group the
sum of the percentages of naïve and central memory T
cells (TCM), whereas the effector group was constituted
by the sum of the percentages of terminally differenti-
ated effector (Teff) and effector memory T cells (TEM).
Regarding immunohistochemistry studies, archival and
baseline tumor samples were assessed centrally for PD-
L1 expression with the Ventana SP263 assay (Ventana
Medical Systems, Inc., Oro Valley, Arizona). Immuno-
histochemical stainings were performed on 2.5-μm tissue
sections, using an automated protocol developed for the
Autostainer Link automated slide staining system
(DAKO, Agilent). All steps were performed on this
staining platform using validated reagents, including
deparaffinization, antigen retrieval (cell conditioning),
and antibody incubation and detection. The following
antibodies were used for IHC: CD8 FLEX (Clone C8/
144B, DAKO; #IR623/IS623), CD4 FLEX (Clone 4B12,
DAKO; #IR649), and FoxP3 (Clone 236A/E7, Abcam;
ab20034). Corresponding tissue sections were acquired
and digitalized using the AxioScan.Z1 system (Zeiss).
Digitalized images were automatically analyzed with the
ZEN 2.3 lite software (Zeiss). The percentage of FoxP3
positivity was considered as ratio of FoxP3-positive cells
on total number of cells.
Combined pericyte and endothelial cell staining for
assessing vessel architecture normalization was per-
formed with confocal microscopy. For immunofluores-
cence staining, deparaffinization and antigen retrieval of
2.5-μm tissue sections were performed. Then slides were
washed twice with TBS-T (0.1% Tween 20), and then
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blocked in TBS-T with 2.5% bovine serum albumin for
30 min before the indicated primary antibody was ap-
plied. Endothelial cells were detected with a mouse
monoclonal antibody against CD31/PECAM-1 (clone
JC/70A, NovusBio; #NB600-562) and pericytes were de-
tected with a rabbit monoclonal antibody against NG2
(clone EPR9195, Abcam; #ab139406). Cells were then
washed with TBS-T and incubated with Alexa Fluor
488- or 555-conjugated secondary antibody (Molecular
Probes). Cell nuclei were stained with DAPI (4’,6-diami-
dino-2-fenilindol) (Sigma). After washing, coverslips
were mounted onto glass microscope slides with Pro-
Long™ Gold antifade reagent (Invitrogen). Images were
acquired using Leica-TCS SP5 MP confocal microscope,
with a HCX PL APO 63× 1.4 NA oil-immersion object-
ive using LAS AF version 2.6 software.
Finally, gene-expression studies in tumor samples were
performed with RNAseq: total RNA from formalin-fixed
paraffin-embedded tissue samples was isolated using the
Maxwell® RSC RNA FFPE kit (#AS1440, Promega) with
the Maxwell® RSC Instrument (Promega) according to
the manufacturer’s protocol. Sequencing libraries were
prepared with the “QuantSeq 3′ mRNA-Seq Library
Prep Kit” (Lexogen, Cat.No. 015). Directional cDNA li-
braries are initiated by reverse transcription with oli-
godT priming and eventually sequenced in single-read
format in a HiSeq 2500 instrument (Illumina).
Sequencing read alignment and quantification and dif-
ferential gene expression analysis was performed in the
Bluebee Genomics Platform, a cloud-based service pro-
vider (www.bluebee.com). Briefly, reads are first trimmed
with bbduk from BBTools (Bushnell B., BBMap, https://
sourceforge.net/projects/bbmap/) to remove adapter se-
quences and polyA tails. Trimmed reads are aligned to
the GRCh38/hg38 genome assembly with STAR v 2.5.
Read counting is performed with HTSeq and differential
gene expression analysis, between the responder and
non-responder conditions, is done with DESeq2. Gene
set enrichment analysis (GSEA) versus the Immune-
SigDB molecular signatures database [28] was performed
on a ranked list of DESeq2 data, where log2FC of genes
showing greater than 1.2 absolute fold change was di-
vided by their corresponding p value.
Aims and statistical analysis
The sample size was designed to study immunodynamics
in peripheral blood and in tumor, while gathering effi-
cacy and toxicity data. Thus, the primary aim was to
compare different PBMC subpopulations (at baseline or
during treatment) among patients showing benefit or
not from the combination. Since the patients enrolled in
this trial were at advanced treatment lines and one of
the two study drugs was one to which they had already
experienced treatment failure (bevacizumab), we consid-
ered that those patients that did not experience disease
progression at the standard landmark for immune-
oncology drugs evaluation time (16 weeks) were experi-
encing clinical benefit of the study drugs. Those patients
were termed “non-progressors,” as opposed to those
showing progressive disease at week 16 (“progressors”)
for biomarker analysis purposes. Sample size was deter-
mined according to the ability to detect at least a 10%
difference in any given PBMC subpopulation between
progressors and non-progressors. Setting alpha and beta
Fig. 1 Trial design. Patients had to be receiving maintenance treatment with bevacizumab alone as a part of a previous bevacizumab-containing
regimen for advanced disease, after discontinuing the companion agent because of the usual clinical practice reasons (cumulative toxicity or
achievement of maximal disease response). Pre-trial bevacizumab maintenance was allowed at 5 mg/kg weekly, 10 mg/kg q2w, or 15 mg/kg q3w.
When patients experienced disease progression while on bevacizumab treatment become candidates for the trial. Bevacizumab treatment was
never stopped, and the first durvalumab dose was scheduled for infusion on the next planned bevacizumab dose. All patients switched to a 10
mg/kg weekly bevacizumab schedule in case they were receiving it on a different one. A fresh tumor biopsy was obtained within a time-window
of 7 days prior to the first durvalumab dose. In addition, a PBMC sample was obtained on day 1 prior to the first durvalumab dose, and repeated
periodically until disease progression; an additional sample was harvested at the end-of-treatment visit (28 days after coming-off trial). Treatment
continued until disease progression, unacceptable toxicity or investigator decision
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in 5% and 80%, respectively, a minimum of 24 patients
was deemed necessary to discriminate such effect. All
patients receiving at least one dose of study treatment
were included in the safety and efficacy analysis.
The co-primary aim was to determine the overall survival
(OS) and progression-free survival (PFS). Secondary aims
were to study the safety and toxicity of the combination.
The differences between the percentages of leukocyte sub-
types between progressors and non-progressors were com-
pared using a two-tailed Student’s t test after Arcsin
transformation of the data. Variances were compared with the
F test, and Welch’s correction applied when suspected to have
not-equal standard deviation. CD4, CD8, and Tregs infiltration;
PD-L1 staining; and vascular normalization were compared
with a T-test. OS and PFS estimates were compared with the
log-rank test and Kaplan-Meier curves. All tests were two-
tailed and performed with SPSS V.19 software.
Results
Patients and treatment
From June 2016 to July 2018, 26 patients were ac-
crued at the 8 study sites. Their basic demographic
and clinical characteristics are shown in Table 1.
One patient was found to not having a documented
disease progression to bevacizumab maintenance
before entering the trial and was excluded from the
analysis. On average, patients had been exposed to
8.4 months of continuous bevacizumab dosing be-
fore registration. Patients had been on up to 7 lines
of therapy for metastatic disease. Approximately 2/3
and 1/3, respectively, were hormone-positive and
triple-negative breast cancer patients (Table 1). A
CONSORT diagram describing trial accrual and
populations for safety, efficacy, and correlative stud-
ies is shown in Fig. 2.
Table 1 Demographic and baseline clinical characteristics
Characteristic Value








Time (months) from diagnosis of metastatic disease (median, range) 18.1 (2–116)
Time (months) receiving bevacizumab before registration (median, range) 8.4 (1.6–24.7)












ECOG 0 15 (60%
ECOG 1 10 (40%)
PD-L1 expression:
Positive (> 1%) 4 (16%)
Negative (0%) 16 (64%)
Unknown 5 (20%)
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Efficacy
Database lock was performed on February 2019, when pa-
tients had been receiving the study regimen for a median
of 13 weeks (range 4.1 to 57.3 weeks). At this timepoint, 5
patients remained on active treatment for 24+, 28+, 28+,
32+, and 58+ weeks. Median progression-free survival
(PFS) and overall survival (OS) were 3.5 months and 11
months, respectively (Fig. 3a and b). PFS was not signifi-
cantly different for TNBC (triple-negative breast cancer)
and hormone-positive patients (Fig. 3a). Regarding OS,
there was a trend for improved outcomes for the
hormone-positive patients (median OS for TNBC, 7.4
months; median OS for hormone-positives, 19.8months;
P = 0.11; Fig. 3b). The best changes in disease burden and
disease burden changes over time among the 21 patients
with measurable disease are shown in the waterfall plot
and spider plot (Fig. 3c and e). Overall, 28% of the patients
(N = 7) experienced some degree of tumor shrinkage (al-
though 5 of the 7 patients with tumor shrinkage did not
achieve partial response criteria according to RECIST 1.1;
Fig. 3c). The changes in tumor burden were sustained for
at least two cycles among most of the patients achieving
SD or PR, as shown in Fig. 3d. Clinical benefit (CR+PR+
SD) was observed in 15/25 patients (clinical benefit rate −
CBR − 60%) at 8 weeks; at 16 weeks, the CBR was 44%.
Patients experiencing SD or PR showed similar disease-
control duration (Fig. 3e). No complete responses were
observed. Best objective overall responses were as follows:
PR was observed in 2 patients (8%); SD was registered in
10 (40%); with the exception of one patient that did not
reach the first CT scan (4%, non-evaluated; clinical PD),
the remaining 12 patients (48%) experienced PD (total
number of PD: N = 13; 52%). According to the hormonal
status, hormone-positive patients achieved SD in 6/16
cases (37.5%), whereas the rest of the patients (10/16;
62.5% patients) showed PD as best response (one of them
was not evaluated but experienced clinical PD). The two
observed responses (2/9, 22.2%) occurred in TNBC pa-
tients; 2 additional TNBC patients (22.2%) experienced
SD, whereas the remaining TNBC patients (N = 5; 55.6%)
experienced PD as best response. The comparison be-
tween TNBC and hormonal patients regarding the CBR
did not show statistically significant differences (P = 0.73).
Differences in peripheral blood mononuclear cells
(PBMCs) immunophenotyping between progressors and
non-progressors
Seven patients were classified as “non-progressors” whereas
eighteen were classified as “progressors” (statistics section).
The PBMCs analysis of the baseline samples (before the
Fig. 2 CONSORT diagram. Twenty six patients underwent trial screening but one patient was deemed ineligible since she was not found to have
documented progressive disease to ongoing bevacizumab maintenance. The rest of the patients (N = 25) received at least 1 durvalumab dose
and were included in the safety and efficacy analysis. All patients had at least one baseline PBMCs sample for the immune subpopulation
analysis; of them, only 6 consented for the pre-treatment tumor biopsy that was subsequently used for immunohistochemistry and
gene-expression studies
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first durvalumab dose; N = 25) yielded the following results:
first, no differences in the major generic populations (T
cells, monocytes, DCs and NK cells) among progressors
and non-progressors (Figure S4A) were found. In addition,
no baseline differences were evident either in innate
immune populations (Figure S4B, C). Conversely, detailed
analysis of T cell subtypes showed an unusually high fre-
quency of CD4+ T cells in the blood of non-progressors
compared to that of progressors (Fig. 4a). Interestingly, we
observed a strong reduction in the baseline percentage of
Fig. 3 Overall efficacy data. a Kaplan-Meier curves (PFS) for the whole population (left) and split by hormonal subtype (TNBC, 2.6 months;
hormone-positive, 3.3 months; log-rank P value, 0.84). b Kaplan-Meier curves (OS) for the whole population (left) and split by subtype (TNBC, 7.4
months; hormone-positive, 19.8 months; log-rank P value, 0.11). c Waterfall plot showing best percentage change from baseline in the sum of the
longest diameters of target lesions. This plot depicts the changes among the N = 21 patients with measurable disease; the remaining patients
(N = 4) had bone disease only (non-measurable but evaluable disease, according to RECIST 1.1). The patient that was non-evaluated due to
clinical PD was one of the patients with non-measurable disease. d Swimmer plot depicting the time and durability of response of the 25
patients included in the trial. e Spider plot displaying the longitudinal change from baseline in the sum of the longest diameters of target lesions.
It depicts the changes among the same N = 21 patients as in (c). Patients in (c), (d), and (e) are labeled according to their hormonal status: red
dot, hormone-positive; black dot, TNBC
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circulating immunosuppressive T regulatory (Treg) cells in
non-progressors compared to progressors (Fig. 4b). No
other differences between progressors and non-progressors
were evident for naïve, effector (Teff), effector memory
(TEM) and central memory (TCM) CD4
+ or CD8+ T cell
subtypes (Figure S4D, E). The ratio of effector (Teff + TEM)
and non-effector (Tnaïve + TCM) populations were not corre-
lated with the clinical outcome (Figure S4F, G) either.
Regarding the longitudinal analyses in on-treatment sam-
ples, it was revealed that CD8+ TEM and CD8
+ TCM were
increased after the first durvalumab dose compared to the
baseline levels (Fig. 4c); this pattern was attenuated along
subsequent cycles and not observed for CD4+ memory
subsets (Fig. 4d). No other clear differences between non-
progressors and progressors in the frequency of specific T-
cell or innate subpopulations (Figure S5) were found.
Gene-expression patterns and vascular normalization in
tumors from progressors and non-progressors
In an attempt to understand the PBMCs findings in the
context of the mechanism of action of the combination,
we studied tumor biopsies. Six patients (3 non-
progressors and 3 progressors) had available a baseline
tumor biopsy (i.e., after bevacizumab exposure and before
the first durvalumab dose). Non-progressors’ tumors did
not show significant differences in CD8, CD4, or Treg
Fig. 4 Immune cell sub-populations associated to clinical benefit in peripheral blood mononuclear cells. a Frequency of T-cell subtypes
determined by immunophenotyping of PBMC from peripheral blood in non-progressors (red) and progressors (blue) patients in the baseline
sample. b Differential Treg percentage in baseline samples among progressors and non-progressors. c Non-progressors displayed a significant
increase in central memory—and a trend to increase in effector memory—CD8+ T-cells 4 weeks after the first treatment dose, compared with
progressors. d These changes were not evident for CD4+ T cells
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infiltration compared to the progressors (Fig. 5a–c). In
addition, the six baseline biopsies were negative for PD-L1
staining (Fig. 5d). Morphologically, however, the examin-
ation of the vascular network of the baseline samples
displayed pericyte coverage of the endothelial cells in non-
progressors as opposed to progressors (Fig. 5e), indicating
vascular normalization in response to pre-trial bevacizu-
mab exposure in the former [29].
Despite the lack of meaningful morphological or nu-
merical differences in the tumor immune infiltrate, gene
expression revealed profound differences in its func-
tional status. When gene expression levels were queried
for gene set enrichment (GSEAs) against the ImmuneSig
database [28], we found the following differences in im-
munological pathways between non-progressors and
progressors: First, congruently with the observations in
peripheral blood, non-progressors displayed a reduction
of GSEAs related with suppressive activity of FoxP3 Treg
cells, but an enrichment in signatures related to stimu-
lated CD8 T cells (Fig. 5f and h), which suggest an in-
creased effector activity in the tumor tissue. Conversely,
enrichment in active FoxP3 Treg and inactive CD8 cells
signatures were observed in progressors (Fig. 5g and h).
In addition, we observed an enrichment in GSEAs of un-
stimulated resting DCs in progressors versus non-
progressors’ tumors (Fig. 5h). Finally, memory T cell
GSEAs were increased in non-progressors versus pro-
gressors patients (Fig. 5f and h).
Safety
One hundred and six cycles have been administered.
Table 2 shows the incidence of grade 1–2 adverse events
related with the study drugs. There were two grade 3
events possibly related to the study drugs, registered in
the same patient: a patient with lung lymphangitic carcin-
omatosis and previous history of asthma and smoking
habit was admitted with grade 3 respiratory insufficiency,
grade 3 bronchospasm, and grade 2 infection during cycle
2. She received supportive measures, antibiotics, and pred-
nisone and continued on durvalumab + bevacizumab after
discharge without further side effects. The patient was di-
agnosed as COPD exacerbation; thus, the relationship
with the study drugs remains unclear. No grade 4 events
were registered. Four events qualified as severe adverse
events (SAEs): three of them each registered and deemed
related to disease progression in three patients (pain wors-
ening, pancreatitis in a patient with a pancreatic metasta-
sis, and general status decline); the last SAE corresponded
to the patient with grade 3 side effects.
Discussion
In order to ascertain the potential priming role of antian-
giogenic treatment for subsequent immunotherapy, we
conducted a pilot biomarker and efficacy study in advanced
HER2-negative breast cancer patients. Preclinical research
suggests that antiangiogenic agents could exert a priming
of the immune microenvironment [12–15, 17–19, 30]. Par-
ticularly, the sequence in which these agents are adminis-
tered (sequential versus concurrently with immunotherapy)
might be of key importance [25, 26]. The efficacy assess-
ment and the correlative studies results deserve attention.
In our heavily pretreated population, we observed a
PFS of 3.5 months and an OS of 11 months. The re-
sponse rate according to RECIST 1.1 was low (8%), but
the combination achieved a CBR of 60% at 8 weeks and
44% at 16 weeks. The CBR was not significantly different
among TNBC- and hormone-positive patients. Current
evidence suggests that immune checkpoint inhibitors are
more effective in TNBC [31, 32]. We only observed
tumor responses in TNBC; conversely, OS was longer in
the hormonal subtypes. Our sample size precludes de-
finitive conclusions about the long-term efficacy of the
combination, particularly regarding a selective effect of
the combination over one subtype or the other. Most
likely, such overall survival differences may be explained
by the intrinsic biologic differences between TNBC and
the hormonal subtype, which is more benign and usually
displays a 2- to 3-fold longer overall survival in the
metastatic setting. Regardless, the CBR compares favor-
ably in relation with the existing evidence with PD-1/L1
inhibitors monotherapy in similar populations. Although
trial-to-trial comparisons have to be performed with ex-
treme caution, the results of PD-1/L1 inhibitors mono-
therapy trials are as follows: in a single-agent
pembrolizumab study in PD-L1, hormone-positive breast
cancer showed a 20% 16-weeks CBR [4]. Two trials that
accrued a mixed population of hormone-positive and
TNBC patients, testing the efficacy of durvalumab plus
tremelimumab [5] and avelumab [3] respectively, achieved
a < 30% 4-month CBR. In a monotherapy trial with pem-
brolizumab in previously untreated TNBC, the disease
control rate was 23.8% [1], whereas in a previously treated
cohort this rate decreased to just 7.6% [2]. The 4-month
CRB observed in our heavily pretreated cohort is encour-
aging and could be supporting the immuno-priming ef-
fects of bevacizumab. However, our design does not
distinguish between “priming” effects (versus no-priming)
or even whether it is justified or not to maintain bevacizu-
mab in the combination phase. A definitive conclusion in
this regard would require a 2 × 2 randomized design com-
paring the inclusion or not of a bevacizumab priming
phase followed by durvalumab monotherapy or in com-
bination with bevacizumab, together with pre-priming,
pre-durvalumab, and on-treatment PBMC serial sampling.
A recent randomized trial in advanced HER2-negative dis-
ease without targetable molecular alterations in patients
not showing progressive disease after 6–8 chemotherapy
cycles found a lower progression-free survival but longer
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Fig. 5 Tumor tissue immunodynamics and gene expression studies suggest immuno-priming by bevacizumab. Representative
immunohistochemistry images of a CD8+ infiltration, b CD4+ infiltration, and c Treg infiltration in tumors from non-progressor and progressors
patients (upper panels). The lower panels represent the geometric mean and standard deviation of the quantitation data from all available tumor
biopsies. d The six analyzed tumors were negative for PD-L1 expression (applying the 1% boundary), regardless of experiencing benefit or not
from the treatment combination. e Confocal imaging showing representative fields containing normalized blood vessels from a non-progression
(the whole microvessel wall—CD31-positive endothelial cells—is covered by NG2-positive pericytes) and a progressor patient (who, in turn,
displays vessel abnormality—lack of pericyte coverage and tortuous architecture). The chart represents the quantitative differences between the
average percentage of microvessel wall covered by pericytes in non-progressors versus progressors; **P < 0.01. f Functionally representative GSEAs
of the main regulated pathways in non-progressors’ tumors; NES, normalized enrichment score (the higher NES, the higher functional
enrichment); both corrected (false discovery ratio (FDR)) and uncorrected P values are shown. g Same as in (f) for non-responders. h Further
enriched GSEAs in responders and non-responders ranked by their NES; all of them with FDR < 0.001. Scalebars: a–c 20 μm; d 100 μm; e 25 μm
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overall survival of durvalumab compared to maintenance
chemotherapy apparently due to the TNBC patients that
were PD-L1 positive [33]. Thus, the role of durvalumab is
still unclear in advanced HER2-negative breast cancer,
and a randomized study should have a sufficiently large
size in order to be able to stratify patients according to
their hormonal status and PD-L1 expression. Given the
current indications of bevacizumab in breast cancer, and the
fact that the present study was an investigator-initiated trial
with limited funding, our study had to rely necessarily on pa-
tients currently receiving maintenance bevacizumab and seek
for a signal of biologic plausibility for the priming effects in
the set of correlative studies. That restrictive inclusion cri-
teria may constitute on itself a selection bias towards patients
with relatively indolent disease, who do not show immediate
progression while in maintenance bevacizumab (evidenced
by the average time of 8.4months before entering the trial
under bevacizumab-based regimens; Table 1). In fact, bevaci-
zumab itself might not be the most effective VEGF-targeting
drug [21–24] at least in breast cancer, but the investigator-
initiated nature of this trial made bevacizumab the only real-
istic antiangiogenic option for the study. The impressive
effects of other antiangiogenics with high affinity against
VEGFR2 such as lenvatinib (in gastric [34] and endometrial
cancer [35]) or axitinib (in kidney cancer [36]) in combin-
ation with pembrolizumab should make at least consider
these partners in for combination with immunotherapy in
future trials in breast cancer exploring this concept.
The immune-priming hypothesis to explain the clinical
benefit from the combination is further supported by the
immunologic biomarkers found in peripheral blood. Al-
though current evidence of a response-prone immune-
environment (in PBMCs) before treatment with PD-1/L1
inhibitors is lacking in breast cancer [1–5], studies in per-
ipheral blood in other tumor types have shown bio-
markers of benefit from immunotherapy [37–39]. Our
patient population had been exposed to up to 25months
to bevacizumab, and at this point, patients that experi-
enced benefit from subsequent durvalumab displayed an
obvious phenotype consisting in a decreased amount of
immunosuppressive Treg cells in peripheral blood (Fig. 4).
Those patients that had available tissue biopsy showed a
highly congruent gene-expression program, consisting on
decreased expression of gene sets related to Treg cells in
the tumor microenvironment (Fig. 5f–h). Different studies
have established a correlation between aberrant VEGF ex-
pression and the proliferation of Treg cells in the tumor
microenvironment [40–42]. Our results not only support
this local intratumor effect of VEGF blockade on Treg ex-
pansion, but suggest that this effect might be systemic
given the low frequency of Treg cells in peripheral blood of
non-progressors as well. A future randomized study
should confirm whether or not the low number of Treg
cells in these patients is a direct consequence of previous
bevacizumab therapy.
Vascular normalization is the expected positive effect
that translates pharmacodynamic engagement by antian-
giogenics [16]. The fact that the patients that experienced
benefit from the combination and showed the described T
cell phenotype in tumor and peripheral blood were also
those that experienced a vascular normalizing response to
previous bevacizumab exposure (Fig. 5e) further supports
the hypothesis that antiangiogenics can exert an immuno-
priming effect, at least in some cases. Obviously, not all
patients experience vascular normalization in response to
antiangiogenics, which seems to be a factor required for
immuno-priming [17, 18, 30]. We have previously shown
that the normalization rate is agent-dependent (ranging
from 1/3 of the patients with bevacizumab [43] to up to ¾
of the patients with nintedanib [44], in HER2-negative
breast cancer). These differences should be taken into ac-
count for designing future trials. In any case, future
biomarker-based studies in this context should be guided
by peripheral blood sampling; access to fresh tumor biop-
sies in metastatic patients is usually limited (only 25% of
our patients consented to fresh biopsy), and thus, conclu-
sions may not be extrapolable to real-world patients.
Finally, the observed GSEAs suggesting a dysfunctional
DC phenotype in tumors from progressors (Fig. 5h) are
congruent with the role of VEGF in DCs’ maturation
Table 2 Adverse events (grades 1 and 2)
Event Grade 1 Grade 2 Total
Asthenia 4 (16%) 1 (4%) 5 (20%)
Headache 2 (8%) 1 (4%) 3 (12%)
Proteinuria 2 (8%) 0 (0%) 2 (8%)
Hypertension 1 (4%) 1 (4%) 2 (8%)
Diarrhea 2 (8%) 0 (0%) 2 (8%)
Pruritus 0 (0%) 1 (4%) 1 (4%)
Hyporexia 0 (0%) 1 (4%) 1 (4%)
Nausea 0 (0%) 1 (4%) 1 (4%)
Pneumonitis 0 (0%) 1 (4%) 1 (4%)
Thrombosis 0 (0%) 1 (4%) 1 (4%)
Infection 0 (0%) 1 (4%) 1 (4%)
Elevated amylase 1 (4%) 0 (0%) 1 (4%)
Elevated lipase 1 (4%) 0 (0%) 1 (4%)
Rash 1 (4%) 0 (0%) 1 (4%)
Xerosis 1 (4%) 0 (0%) 1 (4%)
Hypothyroidism 1 (4%) 0 (0%) 1 (4%)
Abdominal pain 1 (4%) 0 (0%) 1 (4%)
Vomiting 1 (4%) 0 (0%) 1 (4%)
Pyrexia 1 (4%) 0 (0%) 1 (4%)
Arthralgia 1 (4%) 0 (0%) 1 (4%)
Xerophtalmia 1 (4%) 0 (0%) 1 (4%)
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(progressors also did show vascular abnormality, trans-
lating inadequate effect in clearing VEGF by bevacizu-
mab, which alters DC maturation) and the lack of
benefit from durvalumab. Tolerogenic DCs are associ-
ated to the expansion and differentiation of Treg cells
[45]. The observed decrease of Treg signatures in the
tumor microenvironment might thus be associated to
improved DC maturation.
The main weaknesses for interpretation of our data are
patient heterogeneity and the limited sample size. The
heterogeneity was not only originated by mixing TNBC
and hormone-positive patients: trial patients received a
variable number of treatment lines prior to maintenance
with bevacizumab and also were on maintenance for
highly variable times (from 1.6 to 24.7months). Whereas
patients with many previous treatment lines and long bev-
acizumab maintenance time might be inherently more in-
dolent than the remaining, disease progression also selects
for cancer features associated with refractoriness to im-
munotherapy [46–48]. Trials evaluating PD-1/L1 inhibi-
tors in more advanced disease lines have shown limited
activity compared with earlier lines [1, 2, 31]. Taken to-
gether, these features might complicate the interpretation
of the overall efficacy data and the immunology correlative
studies, at the PBMCs and tumor infiltration levels.
Importantly, no new safety concerns related to durvalu-
mab were detected (Table 2). Although the sample size is
relatively low, all the observed toxic events fit into those
expected either for bevacizumab or durvalumab and do
not suggest any negative drug-drug toxic interaction. It
has been proposed that antiangiogenics can decrease the
amount and severity of immune-related adverse events
(IRAEs) [12]. This trial was not designed for prospective
identification of IRAEs; however, the 8% incidence of diar-
rhea and 4% incidence of rash (plus 2 grade 3 respiratory
events in the same patient, with unclear relationship to
study drugs)—the side effects traditionally most frequently
classified as IRAEs—is not particularly high.
Several trials have studied the simultaneous administration
of antiangiogenics plus immune checkpoint inhibitors in dif-
ferent malignancies [36, 49, 50]. To our knowledge, we are
the first in reporting on the sequential combination in breast
cancer. Our immunophenotyping analyses highlight the pre-
dictive role of specific T cell subtypes for the clinical re-
sponse to PD-L1 blockade, pointing towards several effector
T-lymphocyte subpopulations as biomarkers of activity
(Fig. 4). In the past, single-agent immunotherapy studies in
breast cancer have not shown clear PBMC subpopulations
predicting benefit, suggesting that the response-prone envir-
onment is not obvious in peripheral blood. The fact that in
our study non-progressors showed a differential PBMC pat-
tern compared to the remaining patients after previous ex-
posure to bevacizumab, together with the concurrence of
vascular normalization and gene expression programs
associated to activated Teff cells and reduced immunosup-
pressive Treg in their tumors, suggests a positive immune-
priming effect of bevacizumab. Taken together the positive
efficacy signal, the low toxicity rates, the finding of candidate
biomarkers of activity in peripheral blood, and the biological
rationale, our data justify a larger prospective clinical trial
aiming to define the magnitude of the benefit derived from
antiangiogenic priming in this setting.
Conclusions
The combination of bevacizumab and durvalumab
shows promising efficacy in a heavily pre-treated cohort
of HER2-negative breast cancer patients previously ex-
posed to chronic bevacizumab. Peripheral blood and
tumor immunodynamics suggest that pre-treatment with
bevacizumab immuno-primes at least a fraction of pa-
tients, making them more prone to benefit from durva-
lumab. A prospective randomized trial should confirm
the role of Tregs as potential biomarkers of activity and
the magnitude of benefit of this chemo-free regimen.
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Additional file 1 : Supplementary Figure S1: Flow cytometry gating
strategy for T cells. Representative gating strategy used in T cell
immunophenotyping based on the exclusion of dead cells, the selection
of the lymphoid cells by size and complexity, and then the surface
expression of CD3, CD4, CD8, CCR7 and CD45RA. The combination of
these markers allowed the identification of naïve cells (CCR7+CD45RA+),
Teff (CCR7
−,CD45RA+), TCM (CCR7
+CD45RA−), and TEM (CCR7
−CD45RA−).
Staining with the CD38 marker allowed the identification of activated
cells, which were minimally detected only in Teff and TEM subpopulations.
Additional file 2 : Supplementary Figure S2: Flow cytometry gating
strategy for Treg cells. Representative gating strategy used in Treg cell
immunophenotyping based on the exclusion of dead cells, the selection
of the lymphoid cells by size and complexity, and then the surface
expression of CD3, CD4, CD25, CD127, CCR4, HLA-DR and CD45RO
markers. After the initial selection of CD4+ T cells (CD3+CD4+), Treg cells
were identified as CD25+CD127low double positive cells. The combination
of CCR4 and CD45RO markers allowed the identification of naïve Treg
(CCR4+,CD45RO−) and memory Treg (CCR4
+CD45RO+), whereas HLA-DR
positivity identified activated cells in these Treg subpopulations.
Additional file 3 : Supplementary Figure S3: Flow cytometry gating
strategy for innate cell populations. Representative example of the gating
strategy used for immunophenotyping of the indicated innate
subpopulations. After the exclusion of dead cells, monocytes were
selected by size and complexity; subtypes were identified by CD14 and
CD16 staining, allowing the identification of classical monocytes (CD14+
CD16−), alternative monocytes (CD14−CD16+) and intermediate
monocytes. For DC and NK, leukocytes were selected by size and
complexity in the live cells, and T- and B-lymphocytes excluded by stain-
ing with lineage-specific antibodies. Dendritic cells (DC) and NK cells
were selected within the CD20− and CD14− population; NK cells were
identified as CD56+ cells (both CD16+ and CD16−) and DC as HLA-
DR+CD16− cells. DC subtypes were further defined by CD11c+ (myeloid
DC) or CD123+ (plasmacytoid DC).
Additional file 4 : Supplementary Figure 4: Immunophenotyping of
leukocyte populations in the baseline sample of responders and non-
responder patients. (A-D) Analysis of the indicated leukocyte subtypes in
the baseline blood sample of the patients stratified according to their
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clinical response. The percentages of the main leukocyte subtypes (A),
CD4+ and CD8+ T cells (B), monocyte subtypes (C) and DC subtypes (D)
are shown.
Additional file 5 : Supplementary Figure 5: Longitudinal effects of
treatment on leukocyte populations. For each subpopulation, the time-
dependent increment or decrement during treatment is shown, using
the baseline sample as reference. Red charts: responders; blue charts:
non-responders.
Additional file 6 : Supplementary Table 1: Antibodies used for
immunophenotyping in peripheral blood.
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